<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161393">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01837095</url>
  </required_header>
  <id_info>
    <org_study_id>POL-7</org_study_id>
    <nct_id>NCT01837095</nct_id>
  </id_info>
  <brief_title>Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polyphor Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polyphor Ltd.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to,
      on the day of and on days after treatment with eribulin. Different doses and dosing
      frequencies will be investigated
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability of POL6326 in combination with eribulin in patients with metastatic breast cancer</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence and severity of adverse events and serious adverse events of the combination of POL6326 and eribulin when compared to the adverse event profile of eribulin alone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate of treatment with POL6326 and eribulin in patients with metastatic breast cancer</measure>
    <time_frame>12-24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determination of the complete response (CR) and partial response (PR) in patients treated with the combination of POL6326 and eribulin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>POL6326</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>POL6326</intervention_name>
    <description>POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin</description>
    <arm_group_label>POL6326</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed invasive cancer of the breast.

          -  Presence of at least one measurable lesion per RECIST 1.1 criteria

          -  Stage IV disease by AJCC criteria (7th edition).

          -  HER2 negative (IHC 0,1 or FISH HER2:CEP17 ratio &lt; 2.0)

          -  Must have had treatment with at least 2 but no more than 3 previous regimens in the
             metastatic setting. Previous treatment must have included an anthracycline and taxane
             in either the adjuvant or metastatic setting.

          -  At least 21 days from the completion of any previous cytotoxic chemotherapy or
             biological therapy at time of initiation of POL6326.

          -  ECOG performance status &lt; 2

        Exclusion Criteria:

          -  Previously received eribulin.

          -  Peripheral neuropathy &gt; Grade 2.

          -  Receipt of any other investigational agent within the 28 days prior to Day 1.

          -  Receipt of colony stimulating factor filgrastim, pegfilgrastim, or sargramostim
             within 14 days prior to Day 1.

          -  Radiation therapy within the 14 days prior to Day 1.

          -  Severe concurrent illness or psychiatric illness/social situation that would limit
             compliance with study requirements.

          -  History of other malignancy â‰¤ 5 years previous with the exception of basal cell or
             squamous cell carcinoma of the skin which were treated with local resection only or
             carcinoma in situ of the cervix.

          -  Pregnant or breastfeeding.

          -  Known HIV positivity on combination antiretroviral therapy; these patients are at
             increased risk of lethal infections when treated with marrow-suppressive therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Foluso O Ademuyiwa, M.D.</last_name>
    <phone>(314) 362-7201</phone>
    <email>fademuyi@dom.wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine, Division of Oncology</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Foluso O Ademuyiwa, M.D.</last_name>
      <phone>314-362-7201</phone>
      <email>fademuyi@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Foluso O Ademuyiwa, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 28, 2013</lastchanged_date>
  <firstreceived_date>April 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overall survival</keyword>
  <keyword>Progression free survival</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
